FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease

FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease

The FDA has approved Furoscix ReadyFlow, a furosemide injection designed to treat edema (swelling caused by excess fluid trapped in the body’s tissue) in adults with heart failure or chronic kidney disease .

The product is notable for being the first autoinjector delivering IV-equivalent exposure, potentially allowing for quicker symptom relief and reducing the need for emergency interventions.

Furoscix ReadyFlow provides a full 80 mg/mL dose in a simple, patient- friendly format administered in under 10 seconds.

Heart failure affects approximately 6.7 million adults in the United States and is projected to increase to more than 8 million by 2030.